Akademik Veri Yönetim Sistemi
Turkish Journal of Cancer, cilt.35, sa.1, ss.26-31, 2005 (Scopus)
We aimed to assess the efficacy of neoadjuvant cisplatin and 5-fluorouracil (CF) combination chemotherapy in patients with potentially resectable squamous cell carcinoma of the esophagus. Thirteen consecutive patients with clinically stage III esophagus carcinoma were included in this study. Median age was 55 years (range:27-70 years). All patients were treated by 2 cycles of neoadjuvant chemotherapy (CF) with cisplatin 20 mg/m2/d, iv, and 5-fluorouracil 1000 mg/m2/d, continuous infusion, days 1-5. The objective response rate was 41.6%. Total resection rate was 61.5%. No pathologic complete response was observed. Two patients who underwent curative surgery died on early postoperative period. Five out of 6 resected patients had relapsed disease. Median relapse-free survival was 24 months in patients who had complete resection and the overall survival of all the patients included was 17 months. The results of preoperative chemotherapy with CF combination are not encouraging in patients with squamous cell carcinoma of the esophagus.